A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum

Conditions

obesity

Brief summary

Change in BMI after semaglutide treatment (baseline vs at 6 months of semaglutide treatment), Change in Binge Eating Scale (BES) score after semaglutide treatment (baseline vs at 6 months of semaglutide treatment)

Detailed description

Change in waist/hip ratio after semaglutide treatment (baseline vs at 6 months of semaglutide treatment), Change in body composition after semaglutide treatment (baseline vs at 6 months of semaglutide treatment), Changes in the following after semaglutide treatment (baseline vs at 6 months of semaglutide treatment): Gut hormone blood levels; Blood and urinary DA levels; Appetite-related sensations; DA release in the brain in response to food reward; Neural responses to food reward; Food liking, wanting, and craving; Emotional state; HR and HRV; BP; Chronic hair cortisol levels; SCFA blood levels; Cytokine blood levels; BBB/BSCFB integrity/permeability; Neuroinflammation

Related papers

No related papers found yet.

Interventions

DRUGWegovy 2.4 mg FlexTouch solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change in BMI after semaglutide treatment (baseline vs at 6 months of semaglutide treatment), Change in Binge Eating Scale (BES) score after semaglutide treatment (baseline vs at 6 months of semaglutide treatment)	—

Secondary

Measure	Time frame
Change in waist/hip ratio after semaglutide treatment (baseline vs at 6 months of semaglutide treatment), Change in body composition after semaglutide treatment (baseline vs at 6 months of semaglutide treatment), Changes in the following after semaglutide treatment (baseline vs at 6 months of semaglutide treatment): Gut hormone blood levels; Blood and urinary DA levels; Appetite-related sensations; DA release in the brain in response to food reward; Neural responses to food reward; Food liking, wanting, and craving; Emotional state; HR and HRV; BP; Chronic hair cortisol levels; SCFA blood levels; Cytokine blood levels; BBB/BSCFB integrity/permeability; Neuroinflammation	—

Measure

Time frame

Change in waist/hip ratio after semaglutide treatment (baseline vs at 6 months of semaglutide treatment), Change in body composition after semaglutide treatment (baseline vs at 6 months of semaglutide treatment), Changes in the following after semaglutide treatment (baseline vs at 6 months of semaglutide treatment): Gut hormone blood levels; Blood and urinary DA levels; Appetite-related sensations; DA release in the brain in response to food reward; Neural responses to food reward; Food liking, wanting, and craving; Emotional state; HR and HRV; BP; Chronic hair cortisol levels; SCFA blood levels; Cytokine blood levels; BBB/BSCFB integrity/permeability; Neuroinflammation

—

Outcome results

None listed